Cancer Pediatric clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
9-ING-41 in Pediatric Patients with Refractory Malignancies.
open to eligible people ages up to 22 years
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
at UCSF
Our lead scientists for Cancer Pediatric research studies include Kieuhoa Vo.
Last updated: